Position history for Duquesne Family Office LLC's holdings in Protagonist Therapeutics Inc
Duquesne Family Office LLC holds 159,700 shares of PTGX (Protagonist Therapeutics Inc), worth $16.8M as of 2026-Q1. PTGX represents 0.5% of Duquesne Family Office LLC's portfolio.
Current Value
$16.8M
Current Shares
159,700
Total Value Change
+$6.2M
Total Shares Change
0
Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC, UBS Group AG
Unchanged |
| 159,700 |
0.0% |
| $16.8M |
| 0.5% |
| $91.30 |
0 |
| 2025-Q4 | Unchanged | 159,700 | 0.0% | $13.9M | 0.3% | $87.26 | 0 |
| 2025-Q3 | New | 159,700 | - | $10.6M | 0.3% | $65.14 | 46 |